A rare mixed ovarian tumor associating borderline endometrioid component and borderline serous component

article OA: gold CC0
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-08 ⓘ

This study describes a rare mixed ovarian tumor in a 37-year-old woman, combining borderline endometrioid and borderline serous components, with WT1 staining differentiating the serous portion.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-01 · read from full text ⓘ

This case report describes a rare mixed ovarian tumor in a 37-year-old woman, consisting of both borderline endometrioid and borderline serous components. Pathological evaluation revealed a biphasic structure with distinct immunohistochemical profiles, specifically WT1 positivity in the serous portion and negativity in the endometrioid portion. The authors propose that this co-occurrence highlights the potential role of endometriosis in the genesis of such ovarian tumors, although the exact pathogenic mechanisms involving inflammation and genomic alterations remain incompletely understood. Relevance to endometriosis: the paper explicitly discusses the link between endometriosis and the development of the borderline endometrioid component within this mixed ovarian tumor.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

A 37-year-old woman was admitted to the department of Gynecology and Obstetrics for management of ovarian cyst, for which a left oophorectomy was performed. The specimen was evaluated then in the department of pathology. On gross examination, the ovarian cyst had a smooth surface and measured 5.5x4.5x 2.5cm. Cut section revealed that the cyst was multilocular, filled with clear fluid and containing several buds. Microscopically, the cyst consisted in a biphasic tumor associating borderline endometrioid component, composed of confluent glands of endometrioid-type epithelium with mild atypical nuclei and borderline serous component. This serous component was made by numerous bulbous, irregularly contoured papillae with fibrous cores and lined by pseudostratified columnar cells with moderate atypia. Immunohistochemical study using WT1 showed positive labeling in the borderline serous component (blue asterisk) and absence of labeling in the borderline endometrioid component (red asterisk). The diagnosis of a mixed ovarian tumor associating a borderline endometrioid component and a borderline serous component was given. A mixed tumor associating two types of ovarian borderline tumors is exceptionally described in the literature. In our case, the presence of a borderline endometrioid component associated with a borderline serous component raises the role of endometriosis in the genesis of ovarian tumors. The pathogenetic transformation from endometriosis to ovarian tumors is not fully understood, but it seems mainly related to many factors: inflammation, oxidative stress, hyperestrogenism, and specific genomic alterations.
Full text 1,957 characters · extracted from pmc-nxml · 1 sections · click to expand

Image

A 37-year-old woman was admitted to the department of Gynecology and Obstetrics for management of ovarian cyst, for which a left oophorectomy was performed. The specimen was evaluated then in the department of pathology. On gross examination, the ovarian cyst had a smooth surface and measured 5.5x4.5x 2.5cm. Cut section revealed that the cyst was multilocular, filled with clear fluid and containing several buds. Microscopically, the cyst consisted in a biphasic tumor associating borderline endometrioid component, composed of confluent glands of endometrioid-type epithelium with mild atypical nuclei and borderline serous component. This serous component was made by numerous bulbous, irregularly contoured papillae with fibrous cores and lined by pseudostratified columnar cells with moderate atypia. Immunohistochemical study using WT1 showed positive labeling in the borderline serous component (blue asterisk) and absence of labeling in the borderline endometrioid component (red asterisk). The diagnosis of a mixed ovarian tumor associating a borderline endometrioid component and a borderline serous component was given. A mixed tumor associating two types of ovarian borderline tumors is exceptionally described in the literature. In our case, the presence of a borderline endometrioid component associated with a borderline serous component raises the role of endometriosis in the genesis of ovarian tumors. The pathogenetic transformation from endometriosis to ovarian tumors is not fully understood, but it seems mainly related to many factors: inflammation, oxidative stress, hyperestrogenism, and specific genomic alterations. A) histological findings showing biphasic tumor (HEx100); B) associating borderline endometrioid component (HEx200); C) and borderline serous component (HEx200); D) immunoreactivity with WT1 in the borderline serous component (blue asterisk) and absence of expression in the endometrioid component (red asterisk)

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Female Female Humans Humans

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-15T00:34:46.439362+00:00
License: CC0 · commercial use OK